Management of Rectovaginal Fistula

Initial Approach: Multidisciplinary Medical Control Before Surgery

Rectovaginal fistulas in Crohn's disease require combined medical and surgical management, with medical therapy to control inflammation preceding any surgical intervention, as recommended by the American Gastroenterological Association 1, 2
Anti-TNF therapy (infliximab) is the cornerstone of medical management, achieving prolonged fistula closure in 45% of rectovaginal fistulas, with maintenance therapy extending median closure duration to 46 weeks versus 33 weeks with placebo, according to the European Crohn's and Colitis Organisation 1, 3
Combine anti-TNF agents with immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) both to prevent immunogenicity and maintain remission, as suggested by the American Gastroenterological Association 2, 4
Surgical repair can ONLY proceed after achieving endoscopic healing of the rectosigmoid mucosa, a critical prerequisite that cannot be bypassed, as emphasized by the American Society of Colon and Rectal Surgeons 2, 4, 5

Surgery should only be attempted in patients with disabling symptoms after medical optimization, as there is significant risk of worsening symptoms if the operation fails, according to the American Society of Colon and Rectal Surgeons 2, 4
Advancement Flaps (transanal or transvaginal) are reserved for symptomatic fistulas with healed rectal mucosa and no anorectal stricture or active rectal disease, with a healing rate of 44.2% in combined medical and surgical treatment, as reported by the European Crohn's and Colitis Organisation 2, 4, 6, 7
Gracilis Muscle Interposition achieves 50% healing rate in Crohn's-associated rectovaginal fistulas at 21 months median follow-up, and is considered for complex cases after advancement flap failure, according to the American Society of Colon and Rectal Surgeons 6, 7, 8
Seton Placement is recommended for complex fistulas or those with active inflammation, allowing drainage while medical therapy takes effect, as suggested by the American Gastroenterological Association 2, 5

For treatment-refractory cases, fecal diversion with defunctioning ileostomy or colostomy provides early clinical response in 63.8% of patients, though stomas often become permanent with only 16.6% achieving successful reversal, according to the European Crohn's and Colitis Organisation 3
Fecal diversion improves symptoms and quality of life significantly, with a rate of proctectomy after failed temporary diversion of 41.6%, as reported by the American Society of Colon and Rectal Surgeons 3
Proctectomy is the last resort for refractory complex perianal disease despite defunctioning stoma, though it carries substantial risk of non-healing perineal wounds and long-term recurrence, as emphasized by the American Gastroenterological Association 3

Never attempt surgical repair with active rectal inflammation, as this guarantees failure, according to the American Society of Colon and Rectal Surgeons 2, 4
Do not use anal fistula plugs routinely, as they are no more effective than seton removal alone and trend toward more adverse events, as reported by the European Crohn's and Colitis Organisation 6, 7, 8
Advancement flap surgery should not be offered to patients with mild symptoms, as failure can worsen their condition, according to the American Gastroenterological Association 2, 4

Asymptomatic low anal-introital fistulas may not require surgical treatment, as suggested by the American Society of Colon and Rectal Surgeons 5
Monitor chronic fistula tracts for malignancy development, particularly in long-standing cases, according to the American Gastroenterological Association 5